Classys Inc

Classys Inc maintains a strong capital structure with a debt-to-equity ratio of 0.16, indicating a relatively low reliance on debt financing. The company's liquidity position is characterized by a current ratio of 3.69, suggesting it has sufficient short-term assets to cover its short-term liabilities. However, the risk assessment notes that net cash is negative after subtracting total debt, signaling potential liquidity constraints. In terms of profitability, Classys Inc demonstrates a return on equity (ROE) of 23.86% and a return on assets (ROA) of 18.72%, both of which are strong indicators of efficient capital utilization and asset management. These figures suggest the company is generating substantial returns relative to its equity and total assets, which is favorable compared to the industry's typical performance metrics. The company's revenue is concentrated in the advanced medical equipment and technology segment, with no disclosed geographic diversification in the provided data. This concentration may expose the company to specific market risks, particularly in the healthcare sector, where demand can be influenced by regulatory changes and technological advancements. Classys Inc's growth trajectory is supported by its strong operating and net income figures, with operating income at 170.6 billion KRW and net income at 131.9 billion KRW. While specific growth projections for the current and next fiscal years are not provided, the company's consistent financial performance suggests a stable growth outlook. The risk assessment highlights a medium liquidity risk and a low dilution risk. The company's capital structure is relatively conservative, with a low debt-to-equity ratio and a significant equity base. However, the negative net cash position after accounting for total debt indicates a need for careful liquidity management. No dilution sources are explicitly identified in the provided data, and the dilution risk is assessed as low. Recent events and filings are not detailed in the provided data, but the company's strong financial performance and positive analyst estimates suggest a favorable market perception. Analysts have provided a mean price target of 80,857.14 KRW and a median price target of 79,000.00 KRW, with a mean recommendation of 1.68, indicating a generally positive outlook.